Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07144462
EARLY_PHASE1

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases

Sponsor: Neukio Biotherapeutics (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the safety, tolerability and preliminary efficacy of NEUK203-215 , a healthy donor (HD) allogeneic CD19/BCMA-targeted CAR-NK cell product, in participants with severe, refractory autoimmune diseases.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

8

Start Date

2025-09-04

Completion Date

2027-01-14

Last Updated

2025-08-27

Healthy Volunteers

No

Conditions

Interventions

DRUG

Fludarabine

Specified dose on specified days

DRUG

Cyclophosphamide (C)

Specified dose on specified days

GENETIC

NEUK203-215 Injection

Specified dose on specified days

Locations (1)

Shanghai Changzheng Hospital

Shanghai, Shanghai Municipality, China